Luis Álvarez-Vallina, Research Director at Banc de Sang i Teixits, shared on LinkedIn:
“We are delighted to share our new paper in Advanced Science: ‘A Drug-Gated, Modular STAb-T Immunotherapy With External Control’.
This study introduces the first pharmacologically controllable STAb-T system, adding an external ON/OFF switch to our cell-based immunotherapy platform.
The engineered T cells secrete two inactive antibody modules that assemble into a functional T-cell engager only in the presence of a rapalog. This enables:
- Drug-dependent and dose-tunable T-cell activation
- Stringent control of cytotoxic activity
- On-demand antitumor activity in vivo
- A modular design adaptable to different tumor antigens
- A safety-by-design strategy to reduce uncontrolled and off-tumor activity
By combining the localized immune-recruiting capacity of STAb-T cells with reversible pharmacological control, this work provides a new framework for developing safer and more adaptable living cell therapies.
This landmark achievement for the STAb-T platform represents another important step towards the continued development and clinical translation of this technology, driven by the CNIO-HMRIB Cancer Immunotherapy Unit Spanish National Cancer Research Centre (CNIO) CNIO – Spanish National Cancer Research Centre, the Hospital del Mar Research Institute, and the Hospital 12 de Octubre, Banc de Sang i Teixits in collaboration with STAb Therapeutics.
Outstanding work by Susana Luengo Arias, Carmen Domínguez Alonso, PhD, Anaïs Jiménez Reinosoïs, and the entire team of colleagues and collaborators who made this possible.
Thank you all!
Read the article: A Drug-Gated, Modular STAb-T Immunotherapy With External Control.”
Other articles about on OncoDaily.